Placid Jover - 04 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, Chief Human Resources Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Placid Jover
Issuer symbol: TEVA
Transactions as of: 04 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2026, 16:16:10 UTC
Previous filing: 05 Aug 2025
Next filing: 09 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Jover Placid	Executive Vice President, Chief Human Resources Officer	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Placid Jover	06 Mar 2026	0002026165

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Award		+37,982		$0.000000^*	37,982	04 Mar 2026	Ordinary Shares	37,982		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2	Restricted share units were granted on March 4, 2026, with 9,495 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 9,497 vesting on March 4, 2030.
F3	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, Chief Human Resources Officer